[go: up one dir, main page]

HRP20110374T1 - Upotreba anti-cd151 antitijela kod liječenja primarnog raka - Google Patents

Upotreba anti-cd151 antitijela kod liječenja primarnog raka Download PDF

Info

Publication number
HRP20110374T1
HRP20110374T1 HR20110374T HRP20110374T HRP20110374T1 HR P20110374 T1 HRP20110374 T1 HR P20110374T1 HR 20110374 T HR20110374 T HR 20110374T HR P20110374 T HRP20110374 T HR P20110374T HR P20110374 T1 HRP20110374 T1 HR P20110374T1
Authority
HR
Croatia
Prior art keywords
cdr
antibody
seq
use according
sequences
Prior art date
Application number
HR20110374T
Other languages
English (en)
Croatian (hr)
Inventor
Haeuw Jean-Fran�Ois
Goetsch Liliane
Original Assignee
Pierre Fabre Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37866318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110374(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament
Publication of HRP20110374T1 publication Critical patent/HRP20110374T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20110374T 2006-10-18 2007-10-15 Upotreba anti-cd151 antitijela kod liječenja primarnog raka HRP20110374T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0609135A FR2907341B1 (fr) 2006-10-18 2006-10-18 Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
PCT/FR2007/001688 WO2008049990A2 (fr) 2006-10-18 2007-10-15 Utilisation d'un anticorps anti-cd151 pour le traitement du cancer

Publications (1)

Publication Number Publication Date
HRP20110374T1 true HRP20110374T1 (hr) 2011-06-30

Family

ID=37866318

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110374T HRP20110374T1 (hr) 2006-10-18 2007-10-15 Upotreba anti-cd151 antitijela kod liječenja primarnog raka

Country Status (27)

Country Link
US (2) US8178096B2 (uk)
EP (1) EP2079482B1 (uk)
JP (2) JP5757646B2 (uk)
KR (1) KR101521863B1 (uk)
CN (1) CN101528256B (uk)
AT (1) ATE499387T1 (uk)
AU (1) AU2007310763B2 (uk)
BR (1) BRPI0717455A2 (uk)
CA (1) CA2665912C (uk)
DE (1) DE602007012743D1 (uk)
DK (1) DK2079482T3 (uk)
ES (1) ES2361696T3 (uk)
FR (1) FR2907341B1 (uk)
HR (1) HRP20110374T1 (uk)
IL (1) IL198043A (uk)
MA (1) MA30777B1 (uk)
MX (1) MX2009003039A (uk)
NO (1) NO20091919L (uk)
NZ (1) NZ575781A (uk)
PL (1) PL2079482T3 (uk)
PT (1) PT2079482E (uk)
RS (1) RS51729B (uk)
RU (1) RU2464041C2 (uk)
SI (1) SI2079482T1 (uk)
TN (1) TN2009000144A1 (uk)
UA (1) UA99601C2 (uk)
WO (1) WO2008049990A2 (uk)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
FR2929946B1 (fr) * 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
CN102605057A (zh) * 2012-02-28 2012-07-25 芮屈生物技术（上海）有限公司 癌症病变前期CD151的mRNA水平原位杂交检测试剂盒及检测方法和应用
US9982057B2 (en) 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody
BR112018075222A2 (pt) 2016-06-09 2019-03-19 Pelican Therapeutics, Inc anticorpos anti-tnfrsf25
US11608384B2 (en) * 2017-04-05 2023-03-21 Xdcexplorer (Shanghai) Co., Ltd. Humanized anti-TPBG antibody, preparation method therefor, conjugate thereof, and applications

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
JP2003189851A (ja) * 2001-12-28 2003-07-08 Japan Science & Technology Corp 抗ヒトｃｄ１５１モノクローナル抗体産生ハイブリドーマ
JP2003321494A (ja) * 2002-02-26 2003-11-11 Daiichi Fine Chemical Co Ltd プロｍｍｐ−７の活性化調節方法
CA2690973A1 (en) * 2006-06-23 2007-12-27 Paul M. Simon Targeted immune conjugates
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
FR2929946B1 (fr) * 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer

Also Published As

Publication number Publication date
NO20091919L (no) 2009-05-18
IL198043A (en) 2015-03-31
ES2361696T3 (es) 2011-06-21
KR101521863B1 (ko) 2015-05-20
JP2010506888A (ja) 2010-03-04
DE602007012743D1 (de) 2011-04-07
CN101528256B (zh) 2013-10-02
DK2079482T3 (da) 2011-06-14
HK1132904A1 (en) 2010-03-12
CN101528256A (zh) 2009-09-09
AU2007310763B2 (en) 2011-02-17
KR20090067219A (ko) 2009-06-24
CA2665912A1 (fr) 2008-05-02
JP5757646B2 (ja) 2015-07-29
US20120219569A1 (en) 2012-08-30
MX2009003039A (es) 2009-04-02
US8178096B2 (en) 2012-05-15
MA30777B1 (fr) 2009-10-01
WO2008049990A3 (fr) 2008-09-12
FR2907341B1 (fr) 2012-08-17
PT2079482E (pt) 2011-05-25
RU2464041C2 (ru) 2012-10-20
JP2013253084A (ja) 2013-12-19
FR2907341A1 (fr) 2008-04-25
ATE499387T1 (de) 2011-03-15
JP5723420B2 (ja) 2015-05-27
RS51729B (sr) 2011-10-31
US20090324600A1 (en) 2009-12-31
SI2079482T1 (sl) 2011-07-29
CA2665912C (fr) 2014-12-09
WO2008049990A2 (fr) 2008-05-02
IL198043A0 (en) 2011-08-01
TN2009000144A1 (fr) 2010-10-18
UA99601C2 (uk) 2012-09-10
NZ575781A (en) 2012-06-29
AU2007310763A1 (en) 2008-05-02
BRPI0717455A2 (pt) 2013-12-24
EP2079482A2 (fr) 2009-07-22
EP2079482B1 (fr) 2011-02-23
RU2009118440A (ru) 2010-11-27
PL2079482T3 (pl) 2011-07-29

Similar Documents

Publication Publication Date Title
HRP20110374T1 (hr) Upotreba anti-cd151 antitijela kod liječenja primarnog raka
JP7704815B2 (ja) Ｂｃｍａに対する結合分子及びその使用
US10519236B2 (en) Antibodies specific to delta 1 chain of T cell receptor
JP7137474B2 (ja) ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法
HRP20191169T1 (hr) Konjugati antidll3-protutijelo-pbd i njihove uporabe
JP2018070648A5 (uk)
HRP20201939T1 (hr) Anti-c10orf54 antitijela i njihova primjena
JP2016538318A5 (uk)
JP2011046732A5 (uk)
JP2020502271A5 (uk)
JP2013519375A5 (uk)
IL278574B2 (en) Glycan-interacting compounds and methods of use
JP2018127469A5 (uk)
JP2022101693A5 (uk)
RU2012154339A (ru) НОВОЕ АНТИТЕЛО ПРОТИВ c-Met
JP2015509948A5 (uk)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
RU2014138038A (ru) Фармацевтическая композиция для лечения профилактики рака
ME02928B (me) Dll3 modulatori i metode upotrebe
JP2018507220A5 (uk)
PE20050928A1 (es) Combinaciones terapeuticas de anticuerpo anti-igfr1
JP2016536020A5 (uk)
JP2017500028A5 (uk)
ME02371B (me) Sastojci i postupci za dijagnstikovanje i tretman raka
JP2014502955A5 (uk)